Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Common Equity (2016 - 2025)

Haemonetics has reported Common Equity over the past 16 years, most recently at $911.5 million for Q4 2025.

  • Quarterly results put Common Equity at $911.5 million for Q4 2025, up 0.51% from a year ago — trailing twelve months through Dec 2025 was $911.5 million (up 0.51% YoY), and the annual figure for FY2025 was $820.8 million, down 14.49%.
  • Common Equity for Q4 2025 was $911.5 million at Haemonetics, up from $849.2 million in the prior quarter.
  • Over the last five years, Common Equity for HAE hit a ceiling of $960.0 million in Q1 2024 and a floor of $677.1 million in Q3 2021.
  • Median Common Equity over the past 5 years was $835.0 million (2025), compared with a mean of $824.9 million.
  • Biggest five-year swings in Common Equity: rose 24.62% in 2021 and later decreased 14.49% in 2025.
  • Haemonetics' Common Equity stood at $698.5 million in 2021, then rose by 11.08% to $776.0 million in 2022, then rose by 21.57% to $943.3 million in 2023, then dropped by 3.86% to $906.9 million in 2024, then grew by 0.51% to $911.5 million in 2025.
  • The last three reported values for Common Equity were $911.5 million (Q4 2025), $849.2 million (Q3 2025), and $882.3 million (Q2 2025) per Business Quant data.